A network meta-analysis updated in 2017 investigated the predictive role of PD-L1 expression among 2015 NSCLC patients treated with anti-PD-1/PD-L1 antibodies (alone or in combination) by pooling available data derived by all the published studies [15,16]. Here, PDCD1 is linked to non-small cell lung carcinoma.